Walking, shopping, climbing stairs, and household chores—Q-actin™ helps maintain joint flexibility, strength, and comfort to perform these everyday activities. Clinical studies comparing Q-actin to a placebo or glucosamine-chondroitin have demonstrated that just 20 mg of Q-actin was enough to achieve significant improvements in joint health and function.

​

Clinical Study Confirms Q-actin’s Benefits for Joint Health and Mobility

A randomized, placebo-controlled study involving 91 subjects with moderate osteoarthritis demonstrated that Q-actin significantly improved joint function and comfort.  Participants were divided into three groups receiving either a placebo, 20 mg of Q-actin, or 100 mg of Q-actin daily for six months. Following a baseline evaluation, subjects were assessed every 30 days using widely accepted clinical measurement tools for joint health studies:

​

• Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), which measures joint function.

 

• Visual Analogue Scale (VAS), which measures pain reduction.

 

• Lequesne's Functional Index (LFI), which measures joint function and the ability to perform daily activities.

​

Both Q-actin groups (20 mg and 100 mg) significantly outperformed the placebo group, with the 100 mg dose showing the best results across all measures.  Further validation was observed in the dose-dependent nature of the benefits.

 

• 20 mg Q-actin Group: This group experienced a substantial improvement in joint pain, function, and mobility, with a 32–40% gain across all measures.

 

• 100 mg Q-actin Group: Participants receiving the higher dose of 100 mg daily showed even greater benefits, achieving a 40–50% improvement in joint health, pain reduction, and function.

​

The results were published in Current Rheumatology Reviews.

 

​

​

​

​

​

​

​

​

​

 

​​Clinical Study: Q-actin Outperforms Glucosamine-Chondroitin

A randomized, double-blind clinical study demonstrated Q-actin was significantly more effective than glucosamine-chondroitin in alleviating knee discomfort and enhancing mobility.

 

The study, conducted across three countries, involved 122 men and women aged 40-75 with moderate age-related joint health issues. Participants were divided into two groups: one received 1,350 mg of glucosamine-chondroitin daily, while the other took 10 mg of Q-actin twice a day for six months.

 

Participants were assessed at 30, 60, 90, 120, and 180 days using the WOMAC, LFI, and VAS indices. Across all time points, the Q-actin group reported significantly greater improvements in joint health compared to the glucosamine-chondroitin group.

​

​

​

​

​

​

​

​

​

​​​​

 

• WOMAC Scores: At 180 days, the Q-actin group’s WOMAC score decreased substantially to 24.8, reflecting a 70.3% improvement from baseline, compared to a 33.7% improvement in the glucosamine-chondroitin group.

 

• VAS Scores: Starting from similar pain levels, the Q-actin group achieved a 46% reduction in pain, while the glucosamine-chondroitin group saw a 26% reduction.

 

• LFI Scores: Both groups began with comparable joint function difficulties, but over time, the Q-actin group showed a 27% improvement, compared to only 8% in the glucosamine-chondroitin group.

 

All of these results were statistically significant (p < 0.05), with Q-actin consistently outperforming glucosamine-chondroitin at multiple evaluation points and in comparison to baseline.

​

This study was published in the Clinical Interventions in Aging.